Silence Therapeutics Share Discussion Threads

[buywell2] 27/9/2012 13:59

Just take a peak at what Richard the Lion Heart has gone and bought





ORA Capital Partners H1 loss decreases
Sep 25, 2012 (Datamonitor via COMTEX) --

ORA Capital Partners Limited, an investment and holding company, has reported a loss attributable to owners of the parent of GBP1.72 million, or GBP3.78 loss per share, for the six months ended July 31, 2012, compared to loss attributable to owners of the parent of GBP3.1 million, or GBP5.2 loss per share, for the same period ended July 31, 2011.


Revenue from services for the six months ended July 31, 2012 was GBP38,000, compared to GBP34,000 for the same period ended July 31, 2011.

Operating loss for the six months ended July 31, 2012 was GBP1.68 million, compared to an operating loss of GBP3.1 million for the same period ended July 31, 2011.

Total assets as of July 31, 2012 were GBP85.56 million, compared to GBP117.37 million, as of July 31, 2011.

Richard Griffiths, executive Chairman, stated, "Continued uncertainty in financial markets had a further adverse impact on the carrying values of ORA's quoted strategic portfolio business holdings. Looking ahead, there is reason for continued caution in the near term as economies remain vulnerable to Europe's debt crisis and the economic recovery in the US remains tenuous. However, this environment is also adversely affecting the valuations of many good businesses and we will, therefore, continue to maintain a rigorous and highly selective investment approach with a view to exploiting opportunities as they emerge."


He has gone and snaffled 4.3% of Source Bioscience (SBS)

ie 8,825,000 at I reckon an average of circa 9.5p = £838,375




Was it something I said ? ...... I'd like to think so



Welcome aboard your highness .....









Take a Looksee

[buywell2] 27/9/2012 09:37

kmjs

I suggest you learn to read

The Phase I trial is the easiest to pass BUT not all those that pass get approved

ONLY 9% MAKE IT ............. ie the ODDS ARE 11 to 1 that ATU 027 will make it

The Phase II trial is the hardest to pass

[amiright] 26/9/2012 19:07

Sorry Billthebank a) I cant type and b) Buywell 2.5 annoys me.My point is Silence has 3 delivery platforms;at the end of all the rubbish talked there are only about 5 or 6 of any use.All SiRnai and MiRnai need delievery,they will beat Silence's door soon enough.In addition they have ATU 111, a possible wonder drug and ATU 027 is soon to release the final results from phase 1.Buywell and Filbert were both very disparaging on the basis 027 produced only 33% stabilsation in tumours but they all ignore the fact it is aimed at reducing metastatis which is the real deal.How can you stop a tumour when the patient has only 90 days to live?Anyone can kill a tumour given time but can they stop them spreading ?NO.027 might.Clearly ATU027 goes to phase 1B funded by Silence and then they try to license it out.If it gets through phase 2 it's worth £500m plus as its attacking a £4b plus market.The Third Wave has now started and Silence are on the wavefront.

[kmjs] 26/9/2012 15:37

Buywell

9% of those starting Phase I get to market, but 63% of Phase I trials are
successful. Is that not what your link says?

Unless SLN becomes seriously cash rich they would NOT be able to take Atu27
through to market IF it were to get there, so a partner will probably be brought
in no later than Ph II endpoint if not sooner.

One potential avenue for a small Ph II funding could be the Governments £180m
Biomedical Catalyst Fund, set up to "help the Life Sciences sector", but I
would expect any future Ph III to be conducted by a major pharma.

dyor

[billthebank] 26/9/2012 13:44

amiright Can u try that again? I think I got the jist of it though after a second read. bw I have filtered

[amiright] 26/9/2012 13:10

Hardly a one trick pony.They have the very promising 111,and drugs for the liver and lung early stage as well as three of the most promising delivery patforms on the market which is where the excitememnt will be.of the statisitical chances are for RNAi going through these trials afar higher than the average as even you,Buywell 2.5 would understand.Can we just make sure we all remeber that again he is being negative so that when the shares going racing up he is shunned as deramper,bore and elective short term amnesia victim?Your stats are like comparing road traffic accidents world wide and giving that as the average on motorways in UK.

[buywell2] 26/9/2012 09:42

One trick pony it is

And the stats say the chances are VERY slim






Probability of regulatory approval by phase

■Phase I: 9%
■Phase II: 15%
■Phase III: 44%
■Submission: 80%


It is not totally surprising to see that most of the failure occurs in Phase 2 clinical studies. Phase 1 clinical studies are largely focused on safety in man, and have already been broadly tested in a number of animal models before hand. However, at Phase 2 the clinical studies are not only larger so one can discover more regarding toxicities, but it is at this stage that the ability of the drug is usually first tested to see if it is effective in bringing about the required therapeutic effect. This is where many drugs stumble.

[rikky72] 25/9/2012 20:37

Not sure what the fancy financial maths are behind the goodwill calculation, but $20.4m for the Zamore licenses seems a tadette high given that they achieved erm..oh... yes, precisely sweet FA for SLN. Looking back it seems intradigm was by far the weaker partner of the two but I suppose the main thing (as always) was that cash was raised.

Let's hope they can pull in a lot more revenue this half.

I sincerely hope ATU027 succeeds but it would be great to see significant progress on other fronts too as we remain a somewhat vulnerable one trick pony if it hits the buffers.

Good luck all long (especially the long suffering ones!)

[doc robinson] 25/9/2012 17:04

large buy after hrs at 2.495 i wonder who???

[doc robinson] 25/9/2012 17:04

large buy after hrs at 2.495 i wonder who???

[sos100] 25/9/2012 16:08

No quite going according to plan buywell......

[buywell2] 25/9/2012 11:21

SLN ........ TA way OVERBOUGHT

A bit more substance

Can SLN hit the top 3 Fallers board ?

[effy123] 25/9/2012 11:19

Total revenue for six months to 30 June 2012 of £40k.


Is this the "undisclosed" upfront payment for the last two deals announced?


Bit disappointing if it is.

[aquilla] 25/9/2012 11:17

"This share was way OVERBOUGHT"

Buywell seems to react to whatever the share price is doing. Going up he'll be positive, going down, negative.

Pity his one liners don't have a bit more substance.

[buywell2] 25/9/2012 11:14

Correct .... I would suggest this is why folks are selling

ORCA and Richard the Lionheart can't ride to the resue any more

This share was way OVERBOUGHT




FINANCIAL REVIEW

Revenue in the first half of 2012 at GBP0.04m (six months ended 30 June 2011: GBP
0.35m) was below that in the prior year reflecting lower income from licence
partners. Research and development expenditure at GBP1.89m (six months ended 30
June 2011: GBP1.82m) was broadly in line with the prior year. This reflects
continued investment in the Phase I trial of Atu027. Administrative expenses in
the first half of 2012 decreased to GBP1.13m from GBP1.56m (GBP2.00m including
restructuring of the US operations) in the first half of 2011. This reflects
cost savings made as a result of the closure of the US Redwood City operations
in August 2011

The net loss for the half-year before intangible assets impairment charges was
GBP2.96m (six months ended 30 June 2011: GBP3.43m; full year 2011: GBP5.74m). The
Zamore Design rules licences were the main asset held by Intradigm. The
decision to terminate them therefore meant the GBP20.4m goodwill held on the
balance sheet relating to Intradigm had to be written off. After reflecting
these items, the net loss for the half year after taxation was GBP23.53m.

Cash used in operating and investing activities in the first half of the year
amounted to GBP2.72m (six months ended 30 June 2011: GBP2.59m) which left the Group
with cash at bank of GBP0.95m at the period end.

Following the period end, 2012 Silence raised GBP5.45m (GBP5.20m net of expenses)
in a subscription and open offer of shares as well as the issuance of a GBP1.00m
zero coupon convertible bond. This funding is expected to provide cash
resources that will support the Company's operations into the second half of
2014.

RISKS AND UNCERTAINTIES



There are a number of potential risks and uncertainties that could have a
material impact on the Group's performance over the remaining six months of the
financial year and could cause actual results to differ materially from
expected and historical results. The risks (identified and outlined in the
Annual Report and Accounts 2011 in the Directors' Report on pages 18-20, which
does not form part of this interim statement, include:

* Clinical and regulatory risk - our drug trials may not be successful.

* Competition and intellectual property risk - several companies are
developing RNAi technology. Intellectual property may expire before
products are successful commercially.

* Economic and financial risk - with no recurring revenue, the Group is
reliant on receiving additional funds.

[headsup1] 25/9/2012 11:12

Looks very positive to me will be happy to hold for the long term and huge rewards.

[colsound] 25/9/2012 11:09

buywell 20 million of goodwill for Intridigm held on balance sheet, now off balance sheet that's all.. you're trying to spin this to benefit your short opened at 0.75p lol

[spursspurs] 25/9/2012 10:11

buywell u r sooooooooooooo boring!

[buywell2] 25/9/2012 09:42

ORCA and Richard can only buy a few more then they have to bid for the whole POS


SP could now drop to previous lows


That is some LOSS

* Loss for the six months ended 30 June 2012 was GBP23.53m (six months ended 30 June 2011: loss of GBP3.43m)

[geoffmanana] 25/9/2012 08:55

Very positive statement this morning.
Especially "Quark also announced plans to expand development of PF-4523655 in glaucoma increasing the potential milestone payable to SLN on this program BY $24.8m"...note by and not to $24.8m.
Also enough funds to support further development into 2nd half of 2014.
It looks as though SLN are now in a good position going forward.
All in all I'm very happy with this upbeat statement.

[aquilla] 25/9/2012 07:16

Results out:

"With its strong patent position, drugs
in the clinic, unique delivery systems and exciting pre-clinical data, we
believe that the Company will be at the forefront of the new RNAi wave."

[amiright] 24/9/2012 09:48

It is now clear you are a complete and utter waste of chatroom space Buywell2.GOing back to review you have at no stage contributed anything positve to us all making money.ORA and RG have not bought for some time and are unable to if thye are not to break the 29.9% rule.recent buying has been broadspread interest derived from Silence's own apparent improvement in management decisions and actions and by the overall major change in sentiment toward RNAi as the Third Wave begins to emerge.In Silence I would think alleyes should be focussed on the forthcoming ATU027 final phase 1 results and the interpretation that can be placed on this very exciting prospect (which by the way you were dismissive of with your mate Filbert3 when the shares were sub 1p!!).

[buywell2] 24/9/2012 09:23

Chart is at resistance level

ORCA and Richard the Lionheart will have to call in for reinforcements